glucose, (beta-d)-isomer has been researched along with Fractures, Bone in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (86.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jackson, K; Moseley, KF | 1 |
| Pan, H; Shen, J; Zhao, B; Zhao, J | 1 |
| Harindhanavudhi, T; Ruanpeng, D; Sangtian, J; Ungprasert, P | 1 |
| Bilezikian, JP; Hanif, W; Keerthy, D; Kotsa, K; Nirantharakumar, K; Tahrani, AA; Thayakaran, R; Thomas, GN; Toulis, KA | 1 |
| Kaspers, S; Kohler, S; Salsali, A; Woerle, HJ; Zeller, C | 1 |
| Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P | 1 |
| Kaneko, M; Narukawa, M | 1 |
| Aubrey-Bassler, K; Chibrikov, E; Curnew, D; Donnan, JR; Gamble, JM; Grandy, CA; Hache, J; Johnston, K; Marra, CA; Nguyen, H; Swab, M | 1 |
| Blau, JE; Rother, KI; Taylor, SI | 1 |
| Johnsson, E; Johnsson, K; Mansfield, TA; Parikh, SJ; Ptaszynska, A; Yavin, Y | 1 |
| Fioretto, P; Johnsson, E; Mansfield, TA; Parikh, S; Ptaszynska, A; Yavin, Y | 1 |
| Faillie, JL | 1 |
| Hsu, YH; Li, DD; Song, YQ; Tang, HL; Wang, TS; Zhai, SD; Zhang, JJ | 1 |
| Scheen, AJ | 1 |
| Mannucci, E; Monami, M | 1 |
8 review(s) available for glucose, (beta-d)-isomer and Fractures, Bone
| Article | Year |
|---|---|
Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits.
Topics: Accidental Falls; Benzhydryl Compounds; Bone Density; Bone Remodeling; Calcium; Canagliflozin; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Humans; Phosphates; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.
Topics: Adult; Aged; Benzhydryl Compounds; Bone Density; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2018 |
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Topics: Acute Kidney Injury; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetic Ketoacidosis; Fractures, Bone; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections | 2019 |
Pharmacological aspects of the safety of gliflozins.
Topics: Animals; Benzhydryl Compounds; Fractures, Bone; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Lipids; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Incidence; Network Meta-Analysis; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT2 Inhibitors: Benefit/Risk Balance.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fractures, Bone; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Ketosis; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?
Topics: Animals; Benzhydryl Compounds; Bone Density; Canagliflozin; Drug Labeling; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Parathyroid Hormone; Risk; Sodium-Glucose Transporter 2 Inhibitors; United States; United States Food and Drug Administration; Vitamin D | 2017 |
7 other study(ies) available for glucose, (beta-d)-isomer and Fractures, Bone
| Article | Year |
|---|---|
Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bayes Theorem; Benzhydryl Compounds; Bone Density; Canagliflozin; Data Mining; Female; Fractures, Bone; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Pharmacovigilance; Retrospective Studies; Risk Factors; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2021 |
Initiation of dapagliflozin and treatment-emergent fractures.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Risk Factors | 2018 |
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Topics: Adult; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Pancreatitis; Propensity Score; Sodium-Glucose Transporter 2 Inhibitors; Sweden; Urinary Tract Infections; Venous Thromboembolism | 2018 |
Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.
Topics: Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Possible adverse effects of SGLT2 inhibitors on bone.
Topics: Benzhydryl Compounds; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
Topics: Age Factors; Aged; Benzhydryl Compounds; Blood Pressure; Blood Urea Nitrogen; Diuresis; Female; Fractures, Bone; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Hypotension, Orthostatic; Hypovolemia; Incidence; Male; Middle Aged; Osmosis; Placebos; Polyuria; Randomized Controlled Trials as Topic; Risk Factors; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Safety; Urinary Tract Infections | 2016 |